References of "Lucidi, V"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOrthotopic liver transplantation for hepatocellular car- cinoma after successful downstaging: results from the Belgian multicentre cohort
Schreiber, J.; Lerut, J; Verslype, C et al

in Hepatology (Baltimore, Md.) (2014, October), 60(S1), 468550

Purpose: Successful downstaging of hepatocellular carcinoma (HCC) into the Milan criteria (MC) remains a controversial indication for orthotopic liver transplantation (OLT). In Belgium, successful ... [more ▼]

Purpose: Successful downstaging of hepatocellular carcinoma (HCC) into the Milan criteria (MC) remains a controversial indication for orthotopic liver transplantation (OLT). In Belgium, successful downstaging of HCC is an accepted non-standard- ized exception (NSE) for liver allocation. This NSE group rep- resents a unique cohort to analyse if OLT can be safely offered to patients with those extended allocation criteria. The aim of this study is to compare the overall and recurrence free survival after cadaveric OLT between patients with successful downstaging (MILDOWN) and patients always inside the MC (MILIN) from all Belgian transplant centres. Methods: We ret- rospectively analysed all patients listed for OLT with HCC and underlying cirrhosis between 12/2006 and 12/2011 from all Belgian liver transplant centres. Successful downstaging was defined as bringing a patient who was outside the MC into the MC after locoregional therapy (LRT). Results: Overall 381 patients were listed in Belgium during the study period. Of these, 320 received OLT. 248 were MILIN, 62 were MIL- DOWN and 10 were transplanted outside MC. Downstaging treatment included transarterial chemoembolization (TACE; n=26), radiofrequency (RF; n=9), transarterial radioembolisa- tion (TARE; n=4), resection (n=3), percutaneous ethanol injec- tion (n=2) and a combination of the above-mentioned therapies in 18 cases. In the MILIN group 67.3% received locoregional therapy before transplantation, with no significant differences in the distribution of treatment type compared to the MIL- DOWN group. At listing there were no significant differences between the MILIN and MILDOWN group for age, gender and underlying liver disease. Median time on waiting list between the two groups was similar (120 days vs. 115.5 days). Overall survival at 1 year was not significantly different between MILIN and MILDOWN (87.1% vs. 79%; p=0.120). 1.6% of patients were lost to follow-up in both groups. Although not significant, recurrence free survival at 1 year tended to be higher in the MILIN group than in the MILDOWN group (83.9% vs. 74.2%; p=0.073). Conclusion: In this large Belgian multicentre cohort, overall and recurrence free survival at 1 year are not signifi- cantly different between patients who have been downstaged successfully and patients who were always inside the Milan criteria. However, a longer follow up period will define, if the trend of lower survival in the successfully downstaged group becomes significant. Factors associated with HCC recurrence have to be identified. [less ▲]

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailOutcome of patients with hepatocellular carcinoma listed for liver transplantation before and after the MELD-based allocation system within Eurotransplant. A BElgian multicentre retrospective study.
Vos, B.; Rogge, S.; Nevens, F. et al

in Acta Gastro-Enterologica Belgica (2011, March), 74(1), 13

Detailed reference viewed: 30 (3 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation from donation after cardiac death (DCD) donors: Belgian experience 2002-2007
Detry, Olivier ULg; Donckier, Vincent; Lucidi, V. et al

in Acta Gastro-Enterologica Belgica (2009, January), 72(1), 21

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailTransplantation hépatique à partir de donneurs cadavériques à coeur arrêté: expérience multicentrique belge de 58 cas sur 5 ans
Detry, Olivier ULg; Rahmel, Axel; Donckier, Vincent et al

Conference (2008, October 11)

Detailed reference viewed: 37 (14 ULg)